Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Givinostat in Relapsed/Refractory Multiple Myeloma
NCT00792506Phase 2Terminated
- Sponsor
- Italfarmaco
- Start
- Oct 2008
- Primary completion
- Jan 2010
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of givinostat in multiple myeloma (MM), sponsored by Italfarmaco. Primary endpoint: Treatment Emergent Adverse Events at 30 weeks. Started Oct 2008; status: terminated.
02
Drugs
givinostat
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT00792506.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00792506.